Literature DB >> 31656563

Practical management of polyposis syndromes.

Roshani Patel1,2, Warren Hyer1.   

Abstract

Hereditary bowel tumours are usually part of a distinct syndrome which require management of both intestinal and extra-intestinal disease. Polyposis syndromes include: Familial adenomatous polyposis, MUTYH-associated polyposis, Serrated polyposis syndrome, Peutz-Jeghers syndrome, Juvenile polyposis syndrome and PTEN-hamartomatous syndromes. Of all colorectal cancers (CRC), 5%-10% will be due to an underlying hereditary CRC syndrome. Diagnosis and management of polyposis syndromes is constantly evolving as new scientific and technological advancements are made with respect to identifying causative genes and increased sophistication of endoscopic therapy to treat polyps. This, in addition to data yielded from meticulous record-keeping by polyposis registries has helped to guide management in what are otherwise relatively rare conditions. These data help guide clinical management of patients and their 'at-risk' relatives. Diagnosis is both genetic where possible but clinical recognition is key in the absence of an identifiable causative gene. Furthermore, some syndromes can overlap which can additionally complicate diagnosis. The principle goals of polyposis management are first to manage and treat the presenting patient and then to identify 'at-risk' patients, through screening and predictive genetic testing, endoscopic surveillance to allow therapy and guide surgical prophylaxis. Due to the complexity of diagnosis and management, patients and their families should be referred to a genetics centre or a polyposis registry where dedicated management can take place. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  familial adenomatous polyposis; polyposis

Year:  2019        PMID: 31656563      PMCID: PMC6788137          DOI: 10.1136/flgastro-2018-101053

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  35 in total

Review 1.  The risk of gastrointestinal carcinoma in familial juvenile polyposis.

Authors:  J R Howe; F A Mitros; R W Summers
Journal:  Ann Surg Oncol       Date:  1998-12       Impact factor: 5.344

2.  Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis: a meta-analysis.

Authors:  A Sinha; P P Tekkis; D C Gibbons; R K Phillips; S K Clark
Journal:  Colorectal Dis       Date:  2010-06-02       Impact factor: 3.788

3.  Upper gastrointestinal cancer in patients with familial adenomatous polyposis.

Authors:  A D Spigelman; C B Williams; I C Talbot; P Domizio; R K Phillips
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  British Thoracic Society Clinical Statement on Pulmonary Arteriovenous Malformations.

Authors:  Claire L Shovlin; Robin Condliffe; James W Donaldson; David G Kiely; Stephen J Wort
Journal:  Thorax       Date:  2017-12       Impact factor: 9.139

Review 5.  Extraintestinal polyps in Peutz-Jeghers syndrome: presentation of four cases and review of the literature. Deutsche Peutz-Jeghers-Studiengruppe.

Authors:  T Vogel; V Schumacher; A Saleh; J Trojan; G Möslein
Journal:  Int J Colorectal Dis       Date:  2000-04       Impact factor: 2.571

6.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.

Authors:  D E Jenne; H Reimann; J Nezu; W Friedel; S Loff; R Jeschke; O Müller; W Back; M Zimmer
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

7.  Juvenile polyposis--a precancerous condition.

Authors:  J R Jass; C B Williams; H J Bussey; B C Morson
Journal:  Histopathology       Date:  1988-12       Impact factor: 5.087

8.  Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study.

Authors:  Sabela Carballal; Daniel Rodríguez-Alcalde; Leticia Moreira; Luis Hernández; Lorena Rodríguez; Francisco Rodríguez-Moranta; Victoria Gonzalo; Luis Bujanda; Xavier Bessa; Carmen Poves; Joaquin Cubiella; Inés Castro; Mariano González; Eloísa Moya; Susana Oquiñena; Joan Clofent; Enrique Quintero; Pilar Esteban; Virginia Piñol; Francisco Javier Fernández; Rodrigo Jover; Lucía Cid; María López-Cerón; Miriam Cuatrecasas; Jorge López-Vicente; Maria Liz Leoz; Liseth Rivero-Sánchez; Antoni Castells; María Pellisé; Francesc Balaguer
Journal:  Gut       Date:  2015-08-11       Impact factor: 23.059

9.  Malignant potential in intestinal juvenile polyposis syndromes.

Authors:  M C Coburn; V E Pricolo; F G DeLuca; K I Bland
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

Review 10.  British Society of Gastroenterology position statement on serrated polyps in the colon and rectum.

Authors:  James E East; Wendy S Atkin; Adrian C Bateman; Susan K Clark; Sunil Dolwani; Shara N Ket; Simon J Leedham; Perminder S Phull; Matt D Rutter; Neil A Shepherd; Ian Tomlinson; Colin J Rees
Journal:  Gut       Date:  2017-04-27       Impact factor: 23.059

View more
  4 in total

1.  Liver metastasectomy-cytoreductive surgery- hyperthermic intraperitoneal chemotherapy and ileal pouch-anal anastomosis: A case report.

Authors:  Leonidas Chardalias; Antonios Gklavas; Ira Sotirova; Erasmia Vlachou; John Kontis; Ioannis Papaconstantinou
Journal:  Int J Surg Case Rep       Date:  2020-06-13

Review 2.  A Potential Role of IL-6/IL-6R in the Development and Management of Colon Cancer.

Authors:  Mimmo Turano; Francesca Cammarota; Francesca Duraturo; Paola Izzo; Marina De Rosa
Journal:  Membranes (Basel)       Date:  2021-04-24

3.  Cancer within the family tree: risks, diagnosis and treatment of juvenile polyposis syndrome.

Authors:  Kyler Kozacek; Ryan Luzano Santos; Michael Abdo; Pedro A Manibusan
Journal:  BMJ Case Rep       Date:  2020-08-18

4.  mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion.

Authors:  Henry Taylor; Dilay Yerlioglu; Claudia Phen; Antje Ballauff; Natalia Nedelkopoulou; Isabel Spier; Inés Loverdos; Veronica B Busoni; Jürgen Heise; Peter Dale; Tim de Meij; Kevin Sweet; Marta C Cohen; Victor L Fox; Emmanuel Mas; Stefan Aretz; Charis Eng; Stephan Buderus; Mike Thomson; Isabel Rojas; Holm H Uhlig
Journal:  Hum Mol Genet       Date:  2021-06-26       Impact factor: 6.150

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.